
Journal of Prevention and Treatment for Stomatological Diseases ›› 2020, Vol. 28 ›› Issue (4): 267-272.doi: 10.12016/j.issn.2096-1456.2020.04.012
• Review Articles • Previous Articles
CLC Number:
[1] | O′Reilly MS, Boehm T, Shing Y , et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997,88(2):277-285. |
[2] | Mohajeri A, Sanaei S, Kiafar F , et al. The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering[J]. Adv Pharm Bull, 2017,7(1):21-34. |
[3] | Zhou S, Zuo L, He X , et al. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: a retrospective comparison with standard chemotherapy[J]. Thorac Cancer, 2018,9(11):1354-1360. |
[4] | Qin RS, Zhang ZH, Zhu NP , et al. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma[J]. BMC Cancer, 2018,18(1):967. |
[5] | 刘书昊, 潘运龙, 覃莉 , 等. 纳米金结合重组人血管内皮抑素对人脐静脉内皮细胞增殖、凋亡及迁移的影响[J]. 中华实验外科杂志, 2018,35(4):645-648. |
Liu SH, Pan YL, Qin L , et al. The effect of the gold nanoparticles combined with endostar on proliferation, apoptosis, migration of human umbilical vein endothelial cells[J]. Chin J Exp Surg, 2018,35(4):645-648. | |
[6] | Nemoto T, Kubota S . Vascular endothelial cadherin is an endostatin receptor[J]. Biologia (Bratislava), 2011,66(4):721-726. |
[7] | Xu X, Mao W, Chen Q , et al. Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway[J]. PLoS One, 2014,9(9):e107463. |
[8] | Zhang Q, Cao J, Xue K , et al. Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma[J]. Onco Targets Ther, 2016,10:145-151. |
[9] | Xiao L, Yang S, Hao J , et al. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis[J]. Cancer Lett, 2015,359(1):148-154. |
[10] | Ning T, Jiang M, Peng Q , et al. Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model[J]. Thorac Cancer, 2012,3(3):229-238. |
[11] | Fu W, Zhuo J, Hu L . Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer[J]. Oncol Lett, 2017,13(1):196-200. |
[12] | Yu M, Han Y, Zhuo H , et al. Endostar, a modified endostatin induces vascular normalization to improve chemotherapy efficacy through suppression of src signaling pathway[J]. Cancer Biother Radiopharm, 2018,33(4):131-138. |
[13] | Li W, Zhao X, Du B , et al. Gold nanoparticle-mediated targeted delivery of recombinant human endostatin normalizes tumour vasculature and improves cancer therapy[J]. Sci Rep, 2016,6:30619. |
[14] | Jin T, Li B, Chen XZ . A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286)[J]. Oncol Res, 2013,21(6):317-323. |
[15] | Jin T, Jiang F, Jin QF , et al. Endostar combined with gemcitabine and cisplatin chemotherapy for patients with metastatic nasopharyngeal carcinoma: an update[J]. Transl Oncol, 2018,11(2):286-291. |
[16] | Chen J, Yao Q, Huang M , et al. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01)[J]. Int J Cancer, 2018,142(10):2130-2138. |
[17] | Chen C, Liu SR, Zhou S , et al. Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: three case reports[J]. Medicine (Baltimore). 2019,98(32):e16592. |
[18] | Lu S, Li L, Luo Y , et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer[J]. J Thorac Oncol, 2015,10(1):206-211. |
[19] | Chen J, Qi J, Yu B , et al. A retrospective study to compare five induction chemotherapy regimens prior to radiotherapy in the reduction of regional lymph node size in patients with nasopharyngeal carcinoma[J]. Med Sci Monit, 2018,24:2562-2568. |
[20] | Zhang K, Wang Y, Yu X , et al. Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth[J]. BMC Cancer, 2017,17(1):899. |
[21] | Liu GF, Chang H, Li BT , et al. Effect of recombinant human endostatin onradiotherapy for esophagus cancer[J]. Asian Pac J Trop Med, 2016,9(1):86-90. |
[22] | Zheng YF, Ge W, Xu HL , et al. Endostar enhances the antitumor effects of radiation by affecting energy metabolism and alleviating the tumor microenvironment in a Lewis lung carcinoma mouse model[J]. Oncol Lett, 2015,10(5):3067-3072. |
[23] | Zhang L, Ge W, Hu K , et al. Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells[J]. Mol Biol Rep, 2012,39(1):89-95. |
[24] | He L, Zhao C, Li Y , et al. Antiangiogenic effects of recombinant human endostatin in lung cancers[J]. Mol Med Rep, 2018,17(1):79-86. |
[25] | 何朗, 刘康, 陈梅 , 等. 重组人血管内皮抑素联合顺铂不同时相治疗小鼠Lewis肺癌移植瘤疗效观察[J]. 中华肿瘤防治杂志, 2018,25(20):1422-1428. |
He L, Liu K, Chen M , et al. Effect of recombinant human endostatin combined with cisplatin on different stages of Lewis lung cancer xenograft in mice[J]. Chin J Cancer Prev Treat, 2018,25(20):1422-1428. | |
[26] | Chen X, Zhang H, Zhu H , et al. Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer[J]. Tumour Biol, 2016,37(4):4679-4688. |
[27] | Zhu H, Yang X, Ding Y , et al. Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia[J]. Sci Rep, 2015,5:14503. |
[28] | Kareemaghay S, Tavassoli M . Clinical immunotherapeutic approaches for the treatment of head and neck cancer[J]. Int J Oral Maxillofac Surg, 2019,48(4):419-436. |
[29] | Ye W, Liu R, Pan C , et al. Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma[J]. Mol Ther, 2014,22(6):1221-1229. |
[30] | Kang M, Wang F, Liao X , et al. Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma[J]. Medicine (Baltimore), 2018,97(25):e11118. |
[31] | Mardani M, Andishe TA, Ranjbar MA , et al. Serum endostatin levels in oral squamous cell carcinoma[J]. Iran J Otorhinolaryngol, 2018,30(98):125-130. |
[32] | Alahuhta I, Aikio M, Vayrynen O , et al. Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment[J]. Exp Cell Res, 2015,336(1):130-140. |
[33] | Li Y, Jin F, Wu W , et al. Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma[J]. Zhonghua Zhong Liu Za Zhi, 2015,37(2):128-132. |
[34] | Cheng Y, Nie L, Liu Y , et al. Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer[J]. Thorac Cancer, 2019,10(7):1576-1580. |
[35] | Folkman J . Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action[J]. Exp Cell Res, 2006,312(5):594-607. |
[36] | Chen Z, Luo Q, Zhou Z , et al. Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression[J]. Oncotarget, 2017,8(45):79703-79711. |
[37] | Yan M, Dongmei B, Jingjing Z , et al. Antitumor activities of liver-targeting peptide modified recombinant human endostatin in BALB/c-nu mice with hepatocellular carcinoma[J]. Sci Rep, 2017,7(1):14074. |
[38] | Xing S, Fan Z, Shi L , et al. Successful treatment of brain radiation necrosis resulting from triple-negative breast cancer with Endostar and short-term hyperbaric oxygen therapy: a case report[J]. Onco Targets Ther, 2019,12:2729-2735. |
[39] | Li BL, Hu XL, Zhao XH , et al. Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: a clinical study[J]. J Chemother, 2015,27(5):301-306. |
[1] | JI Tong. Diagnosis and treatment of head and neck osteosarcoma [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(9): 545-550. |
[2] | GUO Xiao,DU Xinmei,CHENG Lei,ZHOU Xuedong,LI Mingyun. Research progress on the function and metabolism of d-alanine in bacteria [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(4): 264-267. |
[3] | Chaobin PAN. Research progress in comprehensive and sequential treatment of tongue squamous cell carcinoma [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(5): 273-280. |
[4] | WANG Xing,MENG Jian. Clinical effect of iodine 125 seeds implantation combined with EGFR inhibitor for advanced squamous cell carcinoma in tongue base [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2016, 24(11): 671-673. |
|